Free PSA vs. Total PSA: Differences, Percent-Free PSA, and Next Steps

Direct answer: Total PSA is the amount of prostate-specific antigen measured in blood in both protein-bound and unbound forms. Free PSA is the unbound fraction. Percent-free PSA is calculated from the free and total measurements and may add risk context for selected people with an elevated or borderline total PSA. A lower proportion is generally associated with greater concern in some studied settings, while a higher proportion may be more consistent with a benign explanation. Neither pattern diagnoses or excludes cancer, proves BPH, or independently determines MRI, biopsy, surveillance, or treatment. The result must be interpreted with the assay, prior results, prostate size, medicines, symptoms, examination, and overall risk.

Part of the Ulta Lab Tests Knowledge Center

• For broad PSA levels, temporary influences, preparation, repeat testing, and follow-up, use PSA Levels Explained: Results, Causes and Next Steps.
• See The Complete Guide to Lab Tests and Blood Work for the differences among screening, risk assessment, diagnostic support, and monitoring.
• Explore the broader Men’s Health Blood Tests pillar and Cancer Blood Tests and Tumor Markers pillar.

Key Takeaways

• Total PSA includes free PSA and PSA bound to blood proteins.
• Percent-free PSA is a calculated proportion, not a separate cancer diagnosis.
• Total PSA is commonly the starting measurement; adding free PSA is not automatically better or appropriate for everyone.
• Percent-free PSA may refine risk in selected settings, but there is no universal percentage that automatically requires or avoids biopsy.
• Assay method, age, prostate size, medicines, inflammation, infection, retention, procedures, ejaculation, and biological variation can affect interpretation.
• MRI, risk calculators, clinical examination, selected biomarkers, and biopsy answer different questions.

What PSA Is

PSA is a protein produced mainly by prostate cells. Small amounts normally enter blood. Normal tissue, benign enlargement, inflammation, infection, urinary retention, and prostate cancer can all influence the measured concentration. That is why PSA is prostate-associated but not cancer-specific.

This article focuses only on the free-versus-total comparison. It does not reproduce broad PSA range tables, screening ages, preparation rules, or the full high-PSA pathway owned by the canonical PSA guide.

Total PSA, Free PSA, Bound PSA, and Percent-Free PSA

Total PSA The laboratory measurement that includes PSA circulating free and PSA attached to blood proteins. Free PSA The portion circulating without being attached to those proteins. Bound or complexed PSA The portion attached to proteins in blood. It contributes to total PSA. Percent-free PSA The free concentration expressed as a percentage of the total concentration.

Percent-Free PSA Formula

Percent-free PSA = (free PSA ÷ total PSA) × 100

The free and total results must come from a compatible laboratory method and an appropriate specimen. The calculation describes a proportion; it does not calculate a personal probability of cancer by itself.

Testing option	What it measures	Common clinical question	When it may add information	Important limitations
PSA Total Test	Free plus protein-bound PSA	Is the overall PSA concentration appropriate for the purpose and context of testing?	Common starting measurement for informed screening, symptom evaluation, or monitoring	Cannot identify the cause or diagnose cancer
PSA Free and Total Test	Total PSA, free PSA, and a calculated percentage when reportable	Would the free fraction add context to an elevated or borderline total result?	Selected risk-assessment situations after the total result and clinical context are known	Not a universal first-line test or stand-alone imaging, biopsy, surveillance, or treatment rule

Why Total PSA Is Generally Used First

Total PSA has established roles in informed screening, evaluation of selected prostate-related concerns, and clinician-managed monitoring. The initial result can be reviewed with age, risk factors, prostate history, medicines, symptoms, earlier results, and the purpose of testing. If that review leaves a specific uncertainty, the free fraction may add information.

Ordering free PSA for every person can produce a number that has not been validated for the patient’s situation, increase confusion, and lead to unnecessary follow-up. A larger set of values is not automatically more accurate or more clinically useful.

When Free-and-Total PSA May Add Context

A free-and-total measurement may be considered when total PSA is elevated or borderline in a setting where the result could meaningfully change a risk discussion. Its usefulness depends on the assay’s intended use, the laboratory’s reporting rules, the patient’s age, prostate size, prior PSA, digital rectal examination, family history, inherited risk, medicines, recent infection or retention, and whether a biopsy has already been performed.

Some laboratories calculate or interpret percent-free PSA only within defined total-PSA conditions. Those method-specific rules should be read on the actual report rather than treated as universal thresholds.

What a Lower or Higher Percent-Free PSA May Suggest

In selected populations, a lower percent-free PSA has been associated with a greater chance of finding prostate cancer on biopsy, while a higher percentage has been associated more often with benign explanations. An association changes estimated concern; it is not a diagnosis.

• A low percentage does not prove cancer.
• A high percentage does not prove BPH or exclude cancer.
• One percentage cannot determine whether a person should have MRI or biopsy.
• The same percentage may carry different meaning with a different total PSA, assay, age, prostate size, examination, or prior result.
• Published cutoffs are decision aids used within clinical frameworks, not universal pass/fail rules.

Factors That Can Alter or Complicate Interpretation

Factor	Why it matters	Practical review point
Finasteride or dutasteride	Can lower measured PSA and change how the result is interpreted	Report the medicine, dose, and duration; do not stop it without prescriber guidance
Inflammation or urinary infection	Can raise total PSA and make the timing unrepresentative	Review symptoms and whether testing should occur after the condition resolves
Urinary retention	May increase PSA and requires evaluation of bladder emptying	Do not use the percentage to explain retention
Recent prostate or urinary procedure	May temporarily change PSA	Record procedure type and date
Ejaculation or vigorous cycling	May transiently raise PSA in some people	Follow the selected test’s current preparation instructions
Assay or laboratory change	Methods and calibration can differ	Trend comparable results when possible; do not assume interchangeability
Prostate size and age	Change background risk and the amount of benign tissue producing PSA	Use the result within a validated clinical framework
Biological variation	PSA can fluctuate without a new diagnosis	Confirm unexpected results when clinically appropriate

What the Test Can and Cannot Reveal

It May Help

• Describe how much measured PSA is unbound relative to total PSA.
• Refine a prostate-cancer risk estimate in selected people with an appropriate total PSA context.
• Support a conversation about repeat testing, examination, a validated risk calculator, MRI, another biomarker, or biopsy.

It Cannot

• Diagnose or exclude prostate cancer.
• Prove that an elevation comes from BPH, prostatitis, infection, or retention.
• Determine tumor grade, stage, or aggressiveness.
• Replace prostate MRI, tissue biopsy, or pathology.
• Independently determine active surveillance or treatment. Active surveillance applies to selected people with an established cancer diagnosis and is clinician managed.

Educational framework—not a diagnostic or treatment algorithm.

1. Confirm the purpose. Screening, symptom evaluation, post-diagnosis monitoring, and post-treatment monitoring are different uses.
2. Review the total PSA first. Check earlier results, the current laboratory, medicines, symptoms, recent infection, retention, ejaculation, cycling, and procedures.
3. Ask whether the free fraction is validated for this situation. Use the laboratory’s method-specific information and a clinician’s risk framework.
4. Combine information. Age, ancestry, family history, inherited variants, prostate size, examination, and prior biopsy history can change interpretation.
5. Choose the next question. A repeat PSA tests reproducibility; a risk calculator integrates variables; MRI evaluates imaging features; biopsy obtains tissue; pathology establishes diagnosis and grade.
6. Weigh harms. False positives, false negatives, anxiety, incidental findings, biopsy complications, overdiagnosis, and overtreatment belong in the decision.

How Percent-Free PSA Fits With MRI, Biomarkers, and Biopsy

Percent-free PSA is one possible secondary risk marker. A clinician may instead or additionally use a repeat total PSA, digital rectal examination, a validated risk calculator, prostate volume, another selected blood or urine biomarker, or prostate MRI. These tools are not interchangeable and none of them alone confirms cancer.

MRI can identify suspicious areas and help plan a targeted biopsy, but a normal or nonsuspicious MRI does not exclude every clinically significant cancer. When a definitive tissue diagnosis is required, biopsy samples are examined by a pathologist. Read Prostate Cancer Symptoms and Detection for the complete detection pathway.

When Free-and-Total PSA Is Unlikely to Answer the Question

• Sudden fever, chills, retention, severe urinary pain, visible blood, weakness, or rapidly worsening illness.
• A first-line test ordered without knowing why PSA is being measured.
• An isolated free-PSA value without a compatible total PSA from the same context.
• Diagnosis of BPH, prostatitis, urinary infection, pelvic pain, or prostate cancer.
• Selection of active surveillance, staging, recurrence assessment, or treatment without specialist context.
• Comparison with a prior result produced by a noncomparable method.

For BPH, prostatitis, infection, retention, and urinary symptoms, use the focused prostate and urinary symptom guide.

Preparation, Collection, and Assay Consistency

• Follow the current instructions for the exact ordered test; do not assume that every PSA assay has identical preparation.
• Tell the interpreting professional about prescription medicines, nonprescription medicines, supplements, prostate procedures, catheterization, infection, inflammation, and retention.
• Do not stop finasteride, dutasteride, hormone therapy, or any other medicine because of this article or a result.
• For a trend, use comparable assays and laboratories when practical. Record laboratory, method information, collection date, symptoms, and preparation.

Review direct-access testing, preparation, collection, and follow-up before ordering.

How to Review the Laboratory Report

1. Confirm that both free and total PSA were measured from a compatible sample.
2. Check the units for each concentration and whether the percentage was calculated or reported.
3. Read the laboratory’s method-specific comments and intended-use conditions.
4. Compare with earlier results only when assay and clinical purpose are sufficiently similar.
5. Separate a reference interval from a decision threshold and a risk association.
6. Ask what the result changes after symptoms, medicines, examination, risk factors, and patient preferences are included.

Use How to Read and Understand Your Lab Results for help with units, flags, intervals, trends, and analytical variation.

Questions to Ask a Healthcare Professional

1. Why was total PSA measured in my situation?
2. Is percent-free PSA validated and useful at my total PSA and with this assay?
3. Could infection, retention, a procedure, ejaculation, cycling, or medication affect the result?
4. Are my earlier results comparable with this laboratory method?
5. How do prostate size, age, ancestry, family history, and inherited variants affect the estimate?
6. Would repeating total PSA answer a different question than adding free PSA?
7. Would a risk calculator, MRI, or another biomarker add useful information?
8. What are the benefits and harms of biopsy in my situation?

Frequently Asked Questions

What is the main difference between free PSA and total PSA?

Total PSA includes free and protein-bound forms. Free PSA is only the unbound fraction.

How is percent-free PSA calculated?

The free concentration is divided by the total concentration and multiplied by 100. The calculation is meaningful only when the measurements are compatible.

Is a free-and-total PSA test better than total PSA alone?

Not automatically. Total PSA is commonly used first. Adding the free fraction may help only when it addresses a defined question in a validated setting.

Does a low percent-free PSA mean cancer?

No. A lower percentage is associated with greater concern in selected groups, but it does not diagnose cancer or determine biopsy by itself.

Does a high percent-free PSA mean BPH?

No. A higher percentage may be more consistent with a benign explanation in some settings, but it does not prove BPH or exclude cancer.

Is there one percent-free PSA cutoff everyone should use?

No. Published decision points vary by total PSA, assay, population, age, clinical framework, and professional judgment.

Can percent-free PSA replace an MRI?

No. The blood calculation and MRI answer different questions, and either may miss clinically important disease.

Can percent-free PSA tell me whether I need a biopsy?

It can contribute to a shared decision in selected cases, but it should not be the only reason to perform or avoid biopsy.

Can I compare percent-free PSA from different laboratories?

Use caution. Assays and calibration may differ. Trends are most interpretable when methods and collection contexts are comparable.

Is free-and-total PSA used for active surveillance?

Active surveillance is a clinician-managed plan for selected diagnosed cancers. No single free-or-total PSA result establishes or manages that plan by itself.

Free PSA vs. Total PSA: Use the Result as Context, Not a Verdict

Total PSA is usually the starting measurement. Percent-free PSA may refine risk in selected situations, but it cannot diagnose cancer, prove a benign condition, or make an imaging or biopsy decision independently. Use the same assay when possible, document temporary influences and medicines, and review the result within a complete risk assessment.

Primary References

1. Prostate-Specific Antigen (PSA) Test. National Cancer Institute. Updated January 31, 2025.
2. AUA Announces Updates to the Early Detection of Prostate Cancer Guideline. American Urological Association and Society of Urologic Oncology. February 26, 2026.
3. Prostate Cancer Screening Tests. American Cancer Society. Reviewed November 22, 2023.
4. Tests to Diagnose and Stage Prostate Cancer. American Cancer Society.
5. Prostate-Specific Antigen, Total and Free, Serum. Mayo Clinic Laboratories. Current laboratory-method reference reviewed September 2, 2026.

Medical Disclaimer and Commercial Disclosure

This content is educational and does not provide individual diagnosis or treatment. Laboratory testing does not replace medical history, examination, imaging, biopsy, pathology, specialist evaluation, or emergency care.

Ulta Lab Tests offers laboratory-testing services and may link to tests or panels discussed on this page. This content is educational and does not provide individual diagnosis or treatment.

Originally published: September 26, 2024 | Substantively updated: September 2 2026